Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events

European Journal of Clinical Investigation

Volumn 42, Issue 3, 2012, Pages 266-274

  Schmidt, Morten ^a   Johansen, Martin B ^a   Robertson, Douglas J ^b,c   Maeng, Michael ^a   Kaltoft, Anne ^a   Jensen, Lisette O ^d   Tilsted, Hans Henrik ^a   Bøtker, Hans E ^a   Sørensen, Henrik Toft ^a   Baron, John A ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium channel blockers; Cardiovascular disease; Clopidogrel; Drug interactions; Major adverse cardiovascular events; Stents

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; FELODIPINE; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MIBEFRADIL; NIFEDIPINE; NITRENDIPINE; VERAPAMIL;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY STENT; DENMARK; DRUG USE; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POPULATION RESEARCH; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOPLASTY, BALLOON, CORONARY; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DENMARK; DRUG INTERACTIONS; FELODIPINE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK; STENTS; TICLOPIDINE; VERAPAMIL; YOUNG ADULT;

EID: 84856581921     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02579.x     Document Type: Article

References (30)

1. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
2. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
4. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57:1251-63.
5. European Medicines Agency. Public Statement on Interaction Between Clopidogrel and Proton-pump Inhibitors. London: European Medicines Agency; 2010.
6. U.S. Food and Drug Adminstration. Public-health Advisory: Updated Safety Information About a Drug Interaction Between Clopidogrel Bisulfate (Marketed as Plavix) and Omeprazole (Marketed as Prilosec and Prilosec OTC). Silver Spring, MD, USA: U.S. Food and Drug Adminstration; 2009.
7. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1, 4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000;55:843-52.
8. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63.
9. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
10. Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-5.
11. Olesen JB, Gislason GH, Charlot MG, Fosbøl EL, Andersson C, Weeke P et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011;57:409-17.
12. Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schömig A et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605-10.
13. Greenland S, Lash TL, Rothman KJ. Concepts of interaction. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008: pp 71-86.
14. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish civil registration system. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.
15. Schmidt M, Maeng M, Jakobsen CJ, Madsen M, Thuesen L, Nielsen PH et al. Existing data sources for clinical epidemiology: the Western Denmark Heart Registry. Clin Epidemiol 2010;2:137-44.
16. Gaist D, Andersen M, Aarup Al, Hallas J, Gram LF. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997;43:429-33.
17. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
18. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
19. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999;46:354-7.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
21. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193-202.
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
23. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
24. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5.
25. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel. JACC Cardiovasc Interv 2008;1:612-9.
26. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8.
27. Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45:S131-42.
28. Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005;162:1016-23.
29. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30.
30. Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2008:137-9.